Veterinary oncologists are involved in the treatment of cancer in animals. Whether your pet has been previously diagnosed or cancer is suspected, a veterinary oncologist offers a variety of treatment options to prolong your pet’s life and preserve their quality of life as well.

Our veterinary oncologists utilize similar treatment options that are indicated for human cancers, including chemotherapy, immunotherapy, radiation treatment and photodynamic therapies. Recent advancements in treatment options can help reduce your pet’s pain, lengthen the survival period and may even result in complete recovery in many cases.

We now offer Tanovea-CA1 for our lymphoma patients.

Referrals

View Specialists Calendar
Online Referral Form
Downloadable Referral Form

Examination Fees:

The normal initial examination with the Internal Oncology department is $200.00. After the initial examination, Dr. Clifford will prepare a written estimate for any testing, treatment or medications.

Our Doctors of Oncology

Craig Clifford

Craig Clifford
DVM, MS, DACVIM

Read Bio
Kristin Kicenuik

Kristin Kicenuik
DVM, ACVIM

Read Bio

PETS Oncology Service is Excited to Offer Tanovea-CA1 for Our Lymphoma Patients

The U.S. Food and Drug Administration recently announced that it’s given conditional approval for the first new animal drug to treat canine lymphoma. The FDA said the active ingredient in Tanovea-CA1 is rabacfosadine, a substance that kills rapidly growing cancer cells.

Tanovea-CA1 must be prescribed by a licensed veterinarian because professional expertise is needed to correctly diagnose lymphoma in dogs, determine the best treatment, and manage potential side effects. Tanovea-CA1, which comes in a concentrated form, is diluted and given into a vein over 30 minutes. The infusion should be given by or under the supervision of a veterinarian experienced in chemotherapy.

The “CA1” in Tanovea-CA1 means the drug is conditionally approved. Only animal drugs intended for minor species, such as ferrets or fish, or for minor uses in a major species, such as to treat certain types of cancer in dogs, are eligible for conditional approval. Tanovea-CA1’s conditional approval means that when used according to the label, the drug is safe and has a “reasonable expectation of effectiveness” for treating lymphoma in dogs.

At PETS, our oncology service is excited to add this agent to our current list of drugs to treat lymphoma. Dr. Clifford has a great deal of experience with Tanovea-CA1, having been an investigator as part of clinical trials for the past several years and has treated a large number of patients.

If you have any questions regarding the drug or patients that may be eligible, please contact us.